Form 4: Clover Health CEO Reports Stock Sales, RSU Vesting

Jamie L. Reynoso, Clover Health's CEO of Medicare Advantage, reported the sale of 2,012 Class A Common Stock shares under a 10b5-1 plan and the withholding of 8,706 shares for tax obligations.

Summary

• Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp. (CLOV), reported two transactions involving Class A Common Stock.
• On October 3, 2025, 8,706 shares were automatically withheld at a price of $2.59 to cover tax obligations related to the vesting of restricted stock units (RSUs).
• This vesting represented 6.25% of RSUs granted on January 3, 2023.
• The remaining RSUs will vest in equal quarterly installments, with the final vesting on January 3, 2027, contingent on continued service.
• On October 7, 2025, 2,012 shares were sold at a price of $2.65 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Reynoso on March 13, 2025.
• Following these transactions, Mr. Reynoso beneficially owns 3,043,172 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The transactions are largely routine and pre-planned (10b5-1 sale, RSU tax withholding). While an insider sale can be perceived negatively, the pre-arranged nature mitigates this. The RSU vesting is a positive for executive retention. Overall, the filing is neutral to slightly positive due to the planned nature of the transactions and continued executive compensation.

Positives

• The vesting of restricted stock units (RSUs) indicates continued compensation and retention of a key executive.
• The existence of a Rule 10b5-1 trading plan demonstrates pre-planned transactions, reducing concerns about opportunistic insider selling.

Negatives

• The sale of 2,012 shares by a key executive, even under a 10b5-1 plan, represents a reduction in insider ownership.

Future Outlook

The remaining restricted stock units granted to Jamie L. Reynoso will continue to vest in equal quarterly installments, with the final vesting scheduled for January 3, 2027, contingent upon his continued service to the company.

Industry Context

This filing is a routine disclosure of insider transactions and does not provide broader industry context. It reflects an individual executive's compensation and personal trading activities within Clover Health Investments, Corp., a company operating in the Medicare Advantage sector.

Comparison to Industry Standards

• This Form 4 reports standard insider transactions (RSU vesting, tax withholding, and 10b5-1 plan sales).
• These types of transactions are common across publicly traded companies and are not directly comparable to specific industry projects or results.
• The use of a 10b5-1 plan is a standard practice for executives to sell shares in a pre-arranged, compliant manner.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership due to the sale of 2,012 shares, though this was pre-planned. The RSU vesting indicates continued alignment of executive interests with long-term company performance.

Next Steps

• Remaining restricted stock units will vest in equal quarterly installments until January 3, 2027, subject to continued service.

Key Dates

Recommendation

This Form 4 details routine insider transactions, specifically the vesting of restricted stock units, associated tax withholding, and a pre-planned sale under a Rule 10b5-1 plan. These events are generally expected and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. The transactions are relatively small in the context of the executive's total holdings and the company's market capitalization.

Keywords

Clover Health, CLOV, Jamie L. Reynoso, Form 4, Insider Trading, Stock Sale, RSU Vesting, 10b5-1 Plan, Medicare Advantage, Executive Compensation